Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
HR+
How would you approach a premenopausal woman with HR+, HER2- metastatic breast and a PIK3CA mutation?
Answer from: Medical Oncologist at Community Practice
Ovarian ablation of some sort + AI + CDK 4/6 inhibitor. At relapse, consider fulvestrant + alpelisib.
Sign In
or
Register
to read more
7041
Related Questions
Do you continue ovarian suppression for metastatic hormone-positive breast cancer patients who are premenopausal, regardless of line of therapy?
What approach is suggested for extended adjuvant endocrine therapy in a HR+ breast cancer?
How do you select between imlunestrant ± abemaciclib and elacestrant for those with an ESR1 mutation and progressed on AI and CDK4/6 inhibitor for patients with metastatic ER+/HER2- breast cancer?
Would you consider adding adjuvant ribociclib for a patient who has already received 2 years of endocrine therapy and is eligible for ribociclib according to the NATALEE trial?
How does the safety profile of Dato-DXd influence its use in patients with comorbidities or frailty compared to standard chemotherapy?
What adjuvant therapy would you offer a postmenopausal woman with a new pT2N0 HR+/HER2+ breast cancer primary who is concurrently being treated with anastrozole/ribociclib for well controlled oligometastatic HR+/HER2- disease?
What additional risk features, if any, would sway you to offer chemotherapy in premenopausal women with ER+ HER2- node positive patients whose Oncotype is < 11?
How will you weigh the positive PFS but negative OS benefit when discussing Dato-DXd with patients?
Would you offer adjuvant ribociclib to a postmenopausal female with ER+ luminal A, node+ breast cancer pT1cN1a grade 2 that didn't require chemotherapy per OncoType, but met NATALEE inclusion criteria?
What adjuvant therapy would you recommend for a woman in her 90s with ER-positive, HER2-positive breast cancer who received neoadjuvant trastuzumab, pertuzumab, and anastrozole, but did not achieve a pathologic complete response?